Letolizumab

Letolizumab

Monoclonal antibody
Type	Single-chain variable fragment
Source	Humanized (from mouse)
Target	tumor necrosis factor-related activation protein
Clinical data
Other names	BMS-986004
ATC code	none
Identifiers
CAS Number	1450981-87-9
ChemSpider	none
UNII	449MIE2SD6
KEGG	D11122
Chemical and physical data
Formula	C1734H2688N466O538S10
Molar mass	38991.90 g·mol^−1

Letolizumab (INN;[1] development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[2]

This drug was developed by Bristol-Myers Squibb.[3]

References

1. World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
2. Budamakuntla L, Shree-Lakshmi HV, Bansal A, Venkatarayaraju SK (2019). "Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India". Psoriasis: Targets and Therapy. 9: 19–27. doi:10.2147/PTT.S154073. PMC 6501705. PMID 31119094.
3. Statement On A Nonproprietary Name Adopted By The USAN Council - Letolizumab, American Medical Association.